Life Sciences Archive » October, 2022

Life Sciences - October, 2022

323 articles

• Direct HIV Med Buyers Seek OK Of $10.8M Bristol-Myers Deal
• Green Groups Can Restart Fluoridated Water Risks Case
• 11th Circuit Doubles Down On Monsanto Ruling
• 7th Circ. Asks Eli Lilly If Drug Discount Appeal Is Premature
• Pilgrim's Wants Out Of Coverage Dispute Over Pollution Suit
• Tylenol Suit Can't Survive 'Fatal' 3rd Circ. Law, J&J Says
• Thermo Fisher Buys Diagnostic Products Firm In $2.6B Deal
• Gov't Contracts of the Month: Sonobuoys, EV Charge Stations
• Chancery Sends Biopharma Co. Proxy Battle Toward Trial
• Gilead Must Post $14M To Keep Ban On Generic Lexiscan
• Music Prof Says Remote Work Denial Violated ADA
• My Favorite Law Prof: How I Learned To Put Law Into Practice
• Catching Up With Delaware's Chancery Court
• Monsanto Settles Roundup Case Prior To Trial Start In Fla.
• 2 Plead Guilty In Avanir Drug Kickback Scheme
• 5 Firms Steer Go-Public Mergers For Taxi App, Biotech Firm
• FTC Pesticide Suit Dusts Off Some Rare Antitrust Tools
• Surgery Patient Was In Dark About Dubious Parts, Jury Hears
• NJ Justices Pass On Review Of Blocked Development
• Celsius Network Gets OK To Auction, GWG To Raise Money
• Whistleblower's Atty Accused of Coercing False Statements
• Sandoz, Teva, Others Face AbbVie Drug Patent Battle
• Tillis Bill Would Restore Patent Eligibility, Reward Innovation
• Idaho Lawmakers Fight For Part In Abortion Suit
• Ariz. Co. Barred From Selling Misbranded Supplements
• More J&J Unit Eye Surgery Patents Survive PTAB Review
• Warby Parker, SmileDirect Hit With User Feedback IP Suits
• Real Estate Rumors: Oxford, Madison Marquette, Brookfield
• Nevada Judge Removes Pot From Controlled Substance List
• UK Litigation Roundup: Here's What You Missed In London
• 'Dexter' Covid Safety Worker Hits ViacomCBS With Bias Suit
• Surgery Parts Were Made At Basic Metal Shop, Jury Hears
• Gilead Seeks Win In Gov't's 'Unprecedented' HIV Drug IP Suit
• Biogas Plant's Late Depo Bid Nixed In $100M Colo. Dispute
• McKinsey Loses Opioid Dismissal Bid Amid Deal With Others
• Class, Biotech Co. Propose $10.65M Deal To End Merger Suit
• Fed. Circ. Chief Judge Implores More Education On Patents
• IP Forecast: ITC To Hear Ericsson 5G Patent Fight With Apple
• Walgreens Says It'll Fight SF Estimate 40K Hooked On Opioids
• How To Stay Ahead Of Inventors' Most Common Patent Trap
• Suit Says Nursing Homes Wrongly Got $35M From CARES Act
• FDA Yanks Menthol E-Cig Products From U.S. Market
• Sanctions Bid In Flint Water Suit Denied As 'Nonsensical'
• Latham Adds Health-Focused Partners In Chicago, DC
• SF Details $8B Opioid Plan As Walgreens Remedy Trial Looms
• Veolia Exec To Be Deposed Over Alleged Flint Juror Targeting
• Pharmacies Win Temporary Freeze Of Ohio Opioid Injunction
• Full 9th Circ. Won't Revisit Bar On New Prop 65 Label Suits
• Apotex, Slayback Beat Lymphoma Drug Patent Suit In Del.
• Hand Sanitizer Co.'s Ch. 11 Amended With Destruction Deal
• Tepezza Drugmaker Says Label Did Warn Of Hearing Loss
• Real Estate Rumors: Sun Estate, Prologis, Huayi Brothers
• Del. Court Demands Info On $2.7M Atty Fee In Opioid Deal
• Pfizer, Flynn Pharma Find New UK Competition Fine No Better
• Texas Justices Mull Evidence Standard In Crop Damage Case
• State AG Consumer Protection Priorities Beyond The Election
• Ending Juul-Altria Noncompete Changes Nothing, FTC Says
• What To Consider When Leaving BigLaw To Go Solo
• Ex-Edwards Lifesciences Atty Rejoins Greenberg Traurig
• 3M Can't Get New Trial After $50M Earplug Injury Verdict
• Pharma Co. Clarus Gets OK For Ch. 11 Drug Sale
• Experts Debate Impact Of Ga. Abortion Law At Trial
• Holmes And Feds Spar Over New Trial As Balwani Seeks Delay
• Novartis Says Swiss Officials Raided HQ Over Eli Lilly IP Suits
• Michigan AG Won't Give Up On Flint Water Case
• Cybersecurity Expectations Intensify For Medical Device Cos.
• Industry Backs Broad FCA Dismissal Authority At High Court
• Masimo Slams Hedge Fund Attack On Board Vote Defenses
• Novartis Sues Viatris, Others In New IP Fight Over Heart Drug
• Study Warns Life Sciences Cos. May Be In Antitrust Trouble
• California Law Preserves Tylenol Suit In NJ, Court Told
• 2 Rulings Raise Fundamental Cannabis Policy Questions
• Ex-CPSC Commissioner Joins Morgan Lewis In Philly
• Prosecution Wants 60 Months For Vet Over Doping Scheme
• Dow Hit With $56M Punitive Damages In Calif. Cleanup Trial
• Circuits In 'Disarray' Over FCA Intent Standards, Justices Told
• Ga. Abortion Law 'Distressing,' Doctors Say As Trial Kicks Off
• Workers Want Back In On Ga. Sterilizer Emissions Claims
• Radiology Firm Failed To Protect Patient Data, Suit Says
• Texas Agency Wants New Plan For Tainted Sanitizer Disposal
• 'You Cannot Try A Case Like This': Juul Judge Rips Both Sides
• Reexamining Biopharma Medical-Commercial Separation
• DC Circ. Restarts FTC's Endo Appeal Despite Ch. 11
• Boston Scientific Gets Vein Filter Expert, Suit Tossed
• Catching Up With Delaware's Chancery Court
• PTAB Alumina Decision Shows Need to Validate Expert Claims
• Blue Cross Says Amended Monopoly Suit Lists Old Claims
• My Favorite Law Prof: How I Learned Education Never Ends
• Myovant Stock Continues Upward After Accepting $2.9B Deal
• Marijuana Co. Urges Toss Of Drivers' Misclassification Suit
• 9th Circ. Says Free Speech Won't Protect Anti-Abortion Group
• Diagnostics Co. Says Licensee Stole Software To Compete
• Hedge Fund Sues Masimo Corp. In Del. Over Bylaw Changes
• SEC Gets $550K Of Fines In Penny Stock Scam Case
• HIV Drug Pay-For-Delay Claims Too Speculative, Gilead Says
• Navient Collections Halted, Mallinckrodt Faces $1.6B Suit
• 9th Circ. Won't Revive Dentist's Virus Coverage Suit
• SmileDirect Says California Dental Board Can't Delay Trial
• Lens Maker Justified In Firing Black Worker, Pa. Judge Says
• Why Courts Are Rejecting Agencies' Merger Challenges
• Rite Aid Hid Falling PBM Numbers From Investors, Suit Says
• Venue Analysis Following 1st Chinese Patent Office Rulings
• Apple Says Masimo Is The Infringing One In Watch IP Row
• Walmart To Pay $215M In Fla. AG's Latest Opioid Deal
• Del. Chief Judge Says Patent Docket Is Getting Out Of Hand
• ViSalus' $925M TCPA Loss Must Be Reviewed, 9th Circ. Says
• Dow, PPG Hit With $4M Verdict Over Calif. Chemical Cleanup
• NY Fights To Preserve Case Accusing CVS Of Tying Scheme
• Fla. Biz Says Thermo Fisher Stole Its DNA Testing App
• Novartis To Allow Leukemia Drug Generics In Some Areas
• GOP Wants HHS To Explain $1.3B Chinese COVID Test Deal
• Feds Hit Anxiety Treatment Maker For Unapproved Drug Sales
• 6 Tax Considerations For Life Sciences Collaboration Deals
• Physician Renews Bid To Reschedule Psilocybin In 9th Circ.
• Insurers Tell 6th Circ. To Follow Road Map Of Opioid Rulings
• 2 Firms Steer Singaporean Biotech Firm's $400M SPAC Merger
• LabCorp Tells Albright Not To Triple $272M IP Judgment
• FDA Seeks Injunctions Over E-Cig Cos.' Alleged Illegal Sales
• Senators Want Info As US Ponders Extending COVID IP Waiver
• Goodwin, Davis Polk Steer Biotech Firm's Upsized $175M IPO
• Magistrate Says Counterclaims Should Remain In CBD Row
• New-Parent Attorneys Need Automatic Litigation Stays
• Italian Industrial Giant Launches €300M Venture Capital Co.
• 'What's Wrong With You People?': Judge Rips Dow, PPG Attys
• Biotech Firm Investor Says Shares Belong To Her
• Hearing Aid Co. Hid 'Free' Warranty Deductible, Suit Claims
• Iancu-Backed Group Urges Lawmakers To Support Tillis IP Bill
• Real Estate Rumors: Carlo Bellini, Kit Realty, Nuveen
• Associate Skills That Impress Firms In A Cooling Job Market
• Takeda Sues Apotex Over Planned Generic Of Leukemia Drug
• NC Hits 3M, Chemours With Toxic Firefighting Foam Suits
• Pharmacy Groups Urge 10th Circ. To Uphold Okla. PBM Law
• Attorneys Denied $6.8M In Fees After $12.8M Joint Juice Win
• HK Seeks To Relax Revenue Requirements For Startup IPOs
• US Counties Where Women Get Patents Grew Over 30 Years
• Teva Slams Eli Lilly's 'Free Ride' On Migraine IP As Trial Opens
• Ex-Michael Best FERC Expert Jumps To Eversheds Sutherland
• Endo Gets OK For Cash Use After Deal With Creditors
• NM Opioid Case Against Walgreens 'Easy,' AG Says In Finale
• Ex-Genentech Workers Get 6 Mos. Each For Trade Secret Theft
• Lack Of Clarity On FCA Pleading May Prompt Venue Shopping
• Zurich Drops Contractor From $3.7M NY Lab Fire Suit
• Express Scripts Says Classes 'Riddled' With Uninjured Buyers
• J&J Units Accused Of Ripping Off Surgical Screw Designs
• GAO Urges Stronger Medical Consent Oversight At ICE
• Five Firms Vie To Lead Investor Suit On COVID Drug Claims
• Watching The DTSA Court Split On Inevitable Disclosure
• Trump Restricted CDC On COVID Info, House Panel Says
• Feds Want Justices To Back Nixing Of Whistleblower's Suit
• Eli Lilly To Pay Up To $610M For Gene Therapy Biz Akouos
• Rx Delivery Customers Unharmed In Data Breach, Judge Says
• Mallinckrodt Trust Sues To Recover $1.6B Share Buyback
• UnitedHealth Tells Justices Gov't FCA Dismissal Right Is Wide
• Holmes Witness Stands By Testimony But Feels Bad For Son
• CVS, Rite Aid Hit By Suit Claiming Drug Led To Child's Autism
• FTC Pay-To-Block Challenge May Foretell Antitrust Crackdown
• Imerys Insurer Lacks Standing In Ch. 11 Dismissal Try
• Post-TransUnion Ruling Clarifies Data Breach Standing
• Catching Up With Delaware's Chancery Court
• Eli Lilly Gets PTAB To Review More Teva IP On Migraine Drug
• Biotech Co. Wins $16.5M In Multiple Sclerosis Drug Fight
• HHS Told To Figure Out Possible Drug Pricing Reforms
• Calif. Voters To Weigh In On Abortion, Gambling And Tobacco
• Novartis Accused Of 'Ducking And Diving' MS Patent Fight
• High Court Won't Address FCA Pleading Standard
• Dow Experts Testify To Low Risk At Chemical Cleanup Trial
• Blood Analyzer Patent Suit Settles Ahead Of Trial
• Pfizer Gives Justices Rare Shot At Scrutinizing Kickback Ban
• 3M Beats Surgical Blanket Infection Claims At Mo. Jury Trial
• 5th Circ. Backs Dismissal Of Oil Rig Worker's Stroke Suit
• Elizabeth Holmes Can't Subpoena Gov't Witness's Docs
• Prenatal Tech Co. Says Fitch Even Patent Error Cost It Millions
• Teva, Glenmark Won't Get Antitrust Grand Jury Docs
• Lessons From 3 Antitrust Agency Losses In Merger Trials
• Medtronic Defeats Patient's 'Defective' Pump Suit, For Good
• Texas Catheter Maker Hits Rival With Infringement Suit
• State AGs Tell 8th Circ. Youth Transition Ban Isn't Sex Bias
• Tilray Says Wrong Standard Used In Securities Fraud Order
• Loeb & Loeb-Led DiaCarta Unveils $460M SPAC Merger
• DC AG Says Velsicol Responsible For Pesticide Pollution
• The Pot Industry Organization Pushing For Federal Reform
• Alex Jones' Billion-Dollar Penance, Puerto Rico Prunes Debt
• Levi & Korsinsky Says Firm Shortchanged It $500K In Del. Suit
• High Court Could Resolve Thorny Atty-Client Privilege Issue
• Trade Show Co. Asks 9th Circ. To Consider Virus Science
• 1st Circ. OKs Exec's Longer Term In Meningitis Outbreak Case
• Arnold & Porter Litigator Heads To Wilkinson Stekloff
• UK Litigation Roundup: Here's What You Missed In London
• Health Hires: Dentons, Nelson Mullins, Dorsey & Whitney
• Pharmacies To Pay $6.9M To End FCA Overcharging Claims
• Supreme Court Won't Pause Novartis' Gilenya IP Loss
• J&J Ethicon Unit Prevails In 2 Pelvic Mesh Trials
• Health Orgs Push For Early Wins In Surprise Billing Challenge
• Pharmacy Supplier Must Face Ex-Sales Agent's Fraud Suit
• Ex-Yale Med School Worker Gets 9 Years For $40M Tech Theft
• Surgical Robot Co. Settles Antitrust Suit Ahead Of Dec. Trial
• How Much Information Should Cos. Share With Auditors?
• Supplement Co. Signs Deal With FDA For Product Misbranding
• Direct Biologics, Good Works II Sign Potential $1B SPAC Deal
• Fla. Surgeon Says 50 Cent Can't Sue Over Promotional Photo
• Ch. 11 Cheat Sheet: Vital Pharmaceuticals Inc.
• Mallinckrodt Ch. 11 Trustee Settles Acthar Royalty Claims
• Deals Rumor Mill: Toshiba, Exxon Mobil, Brad Pitt
• Holmes' 'Off-Base' Doc Demand Panned By Gov't Witness
• Firms Seek Fee For Deal To Cap Biopharma Co.'s Director Pay
• NC Drugmaker's Ch. 11 Deal With Cardinal Unit Is Approved
• Chancery OKs $12.5M Settlement In Ionis-Akcea Merger Suit
• 2nd Illinois Jury Hears Sterigenics' Emissions Caused Cancer
• Opioid Attys Stress 'Staggering' Costs In 6th Circ. Fee Feud
• Calif. Bellwether Jury Hears Fake Devices Used In Surgeries
• Ohio Justices Take Up Trans Woman's Birth Certificate Fight
• Customers Win $31M Fees In Contact Lens Price-Fixing MDL
• Even Without Promise Of Albright, NPEs Still Prefer WDTX
• 'Stunned' Health Justice IP Atty Wins $800K 'Genius' Grant
• Ohio Appeals Judge's Ruling Blocking 6-Week Abortion Ban
• Exactech To Face MDL Over Artificial Hip Implants
• Pa. AG, City DAs Spar In Court Over Opioid Suit Release
• How 1st Circ. Maine Cannabis Ruling Could Disrupt Business
• Imerys Insurer Says Ch. 11 Should Be Tossed For Bad Faith
• PTAB Ruling Illustrates Key Use For Prior Art References
• Refining Info Governance As E-Discovery Gets More Complex
• Sandoz Fights FDA Exclusivity For Sanofi MS Drug At DC Circ.
• AIG Can't Convince NJ Court To Keep Virus Suit Against Quest
• Fed Circ. Urged To Undo PTAB's Gene-Editing Patent Ruling
• Ex-Theranos Exec Sunny Balwani Won't Get New Fraud Trial
• Clark Love Wants Mesh Settlement Scheme Suit Tossed
• Jury Poll Error Shouldn't Win Atty New Trial, 1st Circ. Told
• SF Litigation Boutique Durie Tangri To Join MoFo
• DOJ Overhauls Walmart Opioid Suit After High Court Decree
• Bang Energy Drink Biz Fizzles Into Ch. 11 After Court Battles
• SEC Fights Hedge Fund Priest's Fraud Verdict Appeal
• EU Clears $11B Celanese Deal For DuPont Unit With Fix
• Justices Asked To Keep Staying Novartis' Gilenya IP Loss
• McKesson Hit With Religious Bias Suit Over Vax Policy
• Chancery Awards $900K Fee For Biopharma Co. Settlement
• Congressional Probes After The Midterms: Tips For Witnesses
• EU Unified Patent Court Launch Date Set For April 1
• IQVIA Unit Faces Pared-Down Trade Secrets Suit
• How The US Merger Enforcement Playbook Is Evolving
• Blank Rome Snags IP Pro For New York Office
• Investor Says Abbott Laboratories Hid Formula Plant Woes
• Opioid Judge Won't Halt 'Waste Of Time' Ohio Trial
• Risk Mitigation In Face Of Rising Legal Malpractice Claims
• Justices Won't Review Sentence In Meningitis Outbreak Case
• EU Accuses Teva Of Misusing IP To Block Rival MS Drugs
• Quest Settles Ravgen Prenatal Test Patent Suit On Eve Of Trial
• Juul Judge Rips Tardy School District's Student Witness List
• Special Master Says DLA Piper Can Rep Co. Suing Amgen Unit
• Alvogen Continues IP Fight Over Cancer Drug Imbruvica
• New Opioid Case Called 'Waste Of Time' Amid 6th Circ. Appeal
• 3 Takeaways From Biden's Cannabis Reform Announcement
• BakerHostetler Accused Of Fraud, Jones Asks For New Hire
• Creditors Say Endo Cash Collateral Conditions Favor Lenders
• Stalled IPO Market Forces Many Companies To Sidelines
• Unpacking FDA's Final Clinical Decision Support Guidance
• Regal Cinemas Asks 9th Circ. To Revive COVID Coverage Suit
• Mediating Teva Kickback Case 'Futile At Present,' Feds Say
• McCarter & English Seeks Cooley Docs In Malpractice Row
• NY Jury Clears CR Bard Of Unlawful Catheter Tying Claims
• Keys To A 9-0 High Court Win: Look For Common Ground
• UK Litigation Roundup: Here's What You Missed In London
• Bayer Promotes Longtime In-House Atty To GC
• IP Forecast: Intel Wants To Restore Suit Over Fortress Patents
• Balwani Wants New Fraud Trial Over Gov't Witness Conduct
• Split 11th Circ. Backs Florida Vaccine Passport Ban
• 'Draconian' Pharmacy Policies Slammed In Opioid Trial
• Business Groups Say Calif. HIV Drug Claims Must Be Tossed
• 8th Circ. Tosses Memory Drug False Ad Suit
• FTC Chair Says Ag Cos. Keeping Food Prices High
• Biden To Pardon Federal Marijuana Possession Convictions
• Defense Lessons From Recent Criminal HIPAA Cases
• Tucker Ellis Nabs Life Sciences IP Pro From Oblon McClelland
• Jury Charge May Taint Aegerion Rep's Drug Fraud Conviction
• Biotech Asks Albright To Triple LabCorp IP Damages To $817M
• SG's Take On Patent Enablement Seen As An Expansion
• Opioid MDL's Verdict Watchdog Deserves DQ, Pharmacies Say
• Proposed Drug Discounts Have Fraud Risks, Watchdog Says
• What Ch. 11 May Mean For Juul As It Fights To Stay On Market
• Patients Urge Fla. Court To Review New Zantac Cancer Study
• FDA Rule Will Wreck Small E-Cig Cos., Suit Says
• Why DOJ's UnitedHealth Merger Loss Is Significant
• Limiting The Scope Of Representation Is Critical For Lawyers
• Justices Told Gilenya Generic Stay Bid Is A Weak Cash Grab
• Dem Reps. Press Biden To Embrace WTO Vaccine IP Waiver
• Bristol-Myers Accused Of COVID Vax Exemption Bias
• Goodwin Procter Adds Partners In LA, San Francisco Offices
• Developers Tied To Pfizer COVID Vaccine Want IP Suit Tossed
• Group Wants To Warn FTC Over 'Fix' For Illumina's Grail Deal
• Paxton Can't Outrun Abortion Subpoena After All, Judge Says
• Nelson Mullins Expands To Philly With Product Liability Trio
• J&J Unit Wins Halt To NM, Miss. Talc Suits
• Holland & Knight DC Tax Pro Lands At Foley & Lardner
• Inside A Boutique's $900M FCA Deal, Its Latest Milestone Case
• Dow, PPG Cleanup Trial Stalls Over City's Expert Disclosure
• Ill. Judge Holds Sanction Bid Over Express Scripts' Doc Dump
• Cherokees, Walmart Settle Opioid Fight Amid 10th Circ. Appeal
• Michigan Officials Dodge Felonies Over Flint Conduct
• Fed. Circ. Casts Doubt On Bid To Revive Lung Drug IP Fight
• Eli Lilly Can't Slip Teva's Migraine Drug Patent Suit
• J&J Mesh Ruling Misread NC Law, 3rd Circ. Is Told
• Shingles Patients Push To Keep Zostavax MDL Alive
• Week After Januvia Patent Is Upheld, Merck Sues Over Generic
• Dr. Oz Class Settlement Shows How Liability Can Diminish
• Novo Nordisk's Transfer Denial Constitutes Bias, EEOC Says
• Justices Balk At Revisiting Vax Mandate For Health Workers
• Supreme Court Says No To 9 Patent Cases
• Chickasaw Suit For Rx Payback Halted For Arbitration
• Judge Won't Hold New Trial In Genetic Testing Patent Feud
• Attys Shouldn't Assume Judicial Critique Is Protected Speech
• Myovant Sees Stock Soar After Rejecting $2.5B Takeover Bid
• J&J Seeks To Erase Talc Fraud Class Claims As Too Late
• Fed. Circ. Unsure Minerva Patent Wrongly Axed By Del. Judge
• Ex-Fed. Circ. Chief Tells Court To Undo Ax Of Tech Patent
• USPTO Wants Thoughts On Boosting Patent 'Robustness'
• Justices Want SG's Take On Skinny Label Patent Case
• 3 Companies Unveil Plans To Go Public Via SPAC Mergers
• Elizabeth Holmes Gets Hearing On Alleged Gov't Misconduct
• Pharma Co. Lied About CBD License To Investors, SEC Says
• Time For Biden And Congress To Fix The ITC
• Catching Up With Delaware's Chancery Court
• Fed. Circ. Reviews ITC Ban On Philip Morris IQOS Devices
• Chinese Vitamin C Cos. Escape 2nd High Court Review
• NC Man's J&J Mesh Suit Was Filed Too Late, 3rd Circ. Rules